Navigation Links
Abbott Announces 11 Percent Increase in Quarterly Dividend
Date:2/20/2009

Company Declares 341st Consecutive Quarterly Dividend

ABBOTT PARK, Ill., Feb. 20 /PRNewswire-FirstCall/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend 11 percent to 40 cents per share.

This marks the 37th consecutive year that Abbott has increased its dividend payout and the 341st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2009, to shareholders of record at the close of business on April 15, 2009.

Abbott has been named by a leading financial media outlet as one of its top five dividend stocks. Additionally, Abbott is a top performer of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 69,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
2. Abbott Announces Earnings Guidance for 2009
3. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
4. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
5. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
6. Abbott Hosts Conference Call for Third-Quarter Earnings
7. Abbott to Present at UBS Best of Americas Investment Conference
8. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
9. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
10. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
11. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
(Date:2/4/2016)... ... , ... Shimadzu Scientific Instruments will showcase several new products, ... sessions, and present on the analysis of mycotoxins and medical cannabis at the ... at the Georgia World Congress Center in Atlanta, Georgia. , Attendees should ...
(Date:2/4/2016)... --> --> ... pleased to provide the following update on recent corporate developments. ... last 3 months we have significantly increased our cash position ... As a result, we have positioned ourselves to execute on ... and expect that development to continue on schedule. ...
(Date:2/4/2016)... , February 4, 2016 ... Laboratories (ABL), Inc. --> Strasbourg, France ... --> PharmaVentures is pleased to announce that it ... its biopharmaceutical manufacturing unit in Strasbourg, France ... --> --> Transgene (Euronext: ...
Breaking Biology Technology:
(Date:2/3/2016)... LIVERMORE, Calif. , Feb. 3, 2016 ... Police Department in Missouri ... of license plate reader (LPR) data from Vigilant Solutions. ... a hit-and-run case in which the victim was walking out ... a parking space next to his vehicle, striking his ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
Breaking Biology News(10 mins):